PRQR — ProQR Therapeutics NV Balance Sheet
0.000.00%
Last trade - 00:00- $199.27m
- $109.67m
- €16.35m
Annual balance sheet for ProQR Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 188 | 94.8 | 119 | 149 | 92.4 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.823 | 57.2 | 1.27 | 2.03 | 5.09 |
| Prepaid Expenses | |||||
| Total Current Assets | 191 | 154 | 121 | 154 | 100 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 17.5 | 16.2 | 16.9 | 14.1 | 12.6 |
| Long Term Investments | |||||
| Total Assets | 210 | 171 | 138 | 168 | 113 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 27.6 | 21.1 | 34.2 | 38.9 | 32.4 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 95.7 | 106 | 96.5 | 79.4 | 63.4 |
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Total Equity | 114 | 65.5 | 41.4 | 88.6 | 49.4 |
| Total Liabilities & Shareholders' Equity | 210 | 171 | 138 | 168 | 113 |
| Total Common Shares Outstanding |